Hanmi Pharm Croissance future

Future contrôle des critères 1/6

Hanmi Pharm devrait augmenter ses bénéfices et son chiffre d'affaires de 6.2% et de 7.5% par an respectivement. Le BPA devrait croître de de 6% par an. Le rendement des capitaux propres devrait être 15.5% dans 3 ans.

Informations clés

6.2%

Taux de croissance des bénéfices

6.0%

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices	33.3%
Taux de croissance des recettes	7.5%
Rendement futur des capitaux propres	15.5%
Couverture par les analystes	Good
Dernière mise à jour	21 Nov 2024

Mises à jour récentes de la croissance future

Recent updates

Risks To Shareholder Returns Are Elevated At These Prices For Hanmi Pharm. Co., Ltd. (KRX:128940)

Nov 19

Does Hanmi Pharm (KRX:128940) Have A Healthy Balance Sheet?

Nov 01

Does Hanmi Pharm (KRX:128940) Deserve A Spot On Your Watchlist?

Oct 17

Hanmi Pharm. Co., Ltd. (KRX:128940) Shares Could Be 36% Below Their Intrinsic Value Estimate

Aug 16

Hanmi Pharm. Co., Ltd. (KRX:128940) Shares Could Be 22% Below Their Intrinsic Value Estimate

Nov 24

Prévisions de croissance des bénéfices et des revenus

KOSE:A128940 - Estimations futures des analystes et données financières antérieures (KRW Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	1,873,608	210,514	250,226	300,764	16
12/31/2025	1,738,424	187,472	227,007	280,653	17
12/31/2024	1,589,127	163,720	253,901	289,507	13
6/30/2024	1,568,781	184,377	198,396	253,078	N/A
3/31/2024	1,533,383	158,086	215,064	266,810	N/A
12/31/2023	1,490,887	146,231	173,029	216,538	N/A
9/30/2023	1,419,708	131,316	93,449	133,068	N/A
6/30/2023	1,397,244	101,982	98,900	139,958	N/A
3/31/2023	1,371,607	106,424	100,087	142,458	N/A
12/31/2022	1,331,547	82,792	111,618	162,269	N/A
9/30/2022	1,330,854	80,780	212,242	258,668	N/A
6/30/2022	1,291,788	78,807	222,898	267,987	N/A
3/31/2022	1,253,997	67,497	242,072	281,103	N/A
12/31/2021	1,203,186	67,025	167,776	201,923	N/A
9/30/2021	1,130,015	77,337	186,309	227,481	N/A
6/30/2021	1,093,865	23,092	145,080	185,482	N/A
3/31/2021	1,057,969	23,462	92,160	139,157	N/A
12/31/2020	1,075,854	11,959	93,785	151,535	N/A
9/30/2020	1,101,450	-1,238	27,417	114,463	N/A
6/30/2020	1,100,225	36,049	-15,536	121,852	N/A
3/31/2020	1,127,208	46,907	-118,323	64,277	N/A
12/31/2019	1,113,650	52,110	-165,540	12,447	N/A
9/30/2019	1,104,465	29,815	-151,837	52,148	N/A
6/30/2019	1,074,014	34,892	-178,529	11,181	N/A
3/31/2019	1,044,929	29,971	-167,121	54,106	N/A
12/31/2018	1,015,962	24,891	-184,829	25,982	N/A
9/30/2018	954,879	41,003	-253,511	-57,022	N/A
6/30/2018	947,203	50,120	-286,240	-61,733	N/A
3/31/2018	928,713	49,170	N/A	-58,807	N/A
12/31/2017	916,586	60,434	N/A	-62,905	N/A
9/30/2017	856,033	12,415	N/A	-499	N/A
6/30/2017	848,177	-3,433	N/A	8,921	N/A
3/31/2017	859,901	4,177	N/A	3,461	N/A
12/31/2016	882,725	23,326	N/A	412,965	N/A
9/30/2016	1,300,579	220,192	N/A	473,881	N/A
6/30/2016	1,349,235	188,682	N/A	439,648	N/A
3/31/2016	1,359,164	179,858	N/A	464,276	N/A
12/31/2015	1,317,535	154,443	N/A	101,712	N/A
9/30/2015	939,070	9,750	N/A	-35,497	N/A
6/30/2015	850,027	37,587	N/A	1,946	N/A
3/31/2015	791,905	33,760	N/A	-35,048	N/A
12/31/2014	761,280	35,510	N/A	-32,820	N/A
9/30/2014	743,779	32,302	N/A	-9,178	N/A
6/30/2014	750,634	45,249	N/A	16,754	N/A
3/31/2014	743,951	45,870	N/A	56,428	N/A
12/31/2013	730,134	43,933	N/A	85,992	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de A128940 ( 6.2% par an) est supérieure au taux d'épargne ( 2.7% ).

Bénéfices vs marché: Les bénéfices de A128940 ( 6.2% par an) devraient croître plus lentement que le marché KR ( 28% par an).

Croissance élevée des bénéfices: Les bénéfices de A128940 devraient augmenter, mais pas de manière significative.

Chiffre d'affaires vs marché: Le chiffre d'affaires de A128940 ( 7.5% par an) devrait croître plus lentement que le marché de KR ( 9.4% par an).

Croissance élevée des revenus: Le chiffre d'affaires de A128940 ( 7.5% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de A128940 devrait être faible dans 3 ans ( 15.5 %).

Hanmi Pharm Croissance future

Future contrôle des critères 1/6

Informations clés

Mises à jour récentes de la croissance future

Consensus EPS estimates increase by 10%

Consensus EPS estimates increase by 10%

Consensus EPS estimates fall by 12%

Consensus EPS estimates increase by 24%

Consensus EPS estimates increase by 13%

Consensus forecasts updated

Recent updates

Risks To Shareholder Returns Are Elevated At These Prices For Hanmi Pharm. Co., Ltd. (KRX:128940)

Investor sentiment deteriorates as stock falls 16%

Does Hanmi Pharm (KRX:128940) Have A Healthy Balance Sheet?

Hanmi Pharm. Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Does Hanmi Pharm (KRX:128940) Deserve A Spot On Your Watchlist?

GC Biopharma and Hanmi Pharmaceutical Receives IND Clearance for Phase 1/2 Clinical Trial from the U.S. FDA

Hanmi Pharm. Co., Ltd. (KRX:128940) Shares Could Be 36% Below Their Intrinsic Value Estimate

Pinning Down Hanmi Pharm. Co., Ltd.'s (KRX:128940) P/E Is Difficult Right Now

Hanmi Pharm. Co., Ltd. to Report First Half, 2024 Results on Jul 30, 2024

Do Hanmi Pharm's (KRX:128940) Earnings Warrant Your Attention?

Hanmi Pharm (KRX:128940) Seems To Use Debt Rather Sparingly

Now 23% undervalued after recent price drop

Now 20% undervalued after recent price drop

A Look At The Intrinsic Value Of Hanmi Pharm. Co., Ltd. (KRX:128940)

Consensus EPS estimates increase by 10%

Hanmi Pharm. Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Hanmi Pharm. Co., Ltd.'s (KRX:128940) Share Price Not Quite Adding Up

Now 21% undervalued after recent price drop

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Now 22% undervalued

New minor risk - Shareholder dilution

Hanmi Pharm. Co., Ltd. to Report Q4, 2023 Results on Feb 02, 2024

Upcoming dividend of ₩490 per share at 0.2% yield

Consensus EPS estimates increase by 10%

Hanmi Pharm. Co., Ltd. to Report Q3, 2023 Results on Nov 01, 2023

Investor sentiment improves as stock rises 20%

Assertio Holdings, Inc. (NasdaqCM : ASRT) completed the acquisition of Spectrum Pharmaceuticals, Inc. (NasdaqGS : SPPI).

Consensus EPS estimates fall by 12%

Hanmi Pharm. Co., Ltd. to Report Q2, 2023 Results on Jul 28, 2023

First quarter 2023 earnings released: EPS: ₩3,467 (vs ₩1,566 in 1Q 2022)

Consensus EPS estimates increase by 24%

Investor sentiment improves as stock rises 19%

Full year 2022 earnings: EPS exceeds analyst expectations

Upcoming dividend of ₩490 per share

Less than half of directors are independent

Consensus EPS estimates increase by 13%

Now 25% undervalued after recent price drop

Consensus forecasts updated

Consensus EPS estimates increase by 28%

Less than half of directors are independent

Now 22% undervalued

Upcoming dividend of ₩490 per share

Hanmi Pharmaceutical Finds New Innovative Potential for Efpeglenatide

Price target increased to ₩385,044

Calculating The Intrinsic Value Of Hanmi Pharm. Co., Ltd. (KRX:128940)

Hanmi Pharm. Co., Ltd., Annual General Meeting, Mar 26, 2021

New 90-day low: ₩319,000

Hanmi Pharm (KRX:128940) Use Of Debt Could Be Considered Risky

New 90-day high: ₩405,000

What Percentage Of Hanmi Pharm. Co., Ltd. (KRX:128940) Shares Do Insiders Own?

New 90-day high: ₩394,000

Hanmi Pharm's (KRX:128940) Stock Price Has Reduced 48% In The Past Five Years

New 90-day high: ₩375,000

Hanmi Pharm. Co., Ltd. (KRX:128940) Shares Could Be 22% Below Their Intrinsic Value Estimate

New 90-day high: ₩327,500

Analysts lower EPS estimates to ₩2,279

Analysts update estimates

Price target raised to ₩342,471

New 90-day high - ₩284,500

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance